Developments: Amgen (Archives 2005-2014)

Parents

2005: $12b (2005)
2010: 1. Amgen - $2.72B (€1.99B) 2010 R&D
2010: Amgen secures approval for two new treatments in 2010.
2010: FDA approved denosumab (Prolia) for the treatment of postmenoposaul women with osteoporosis who are at high risk for fracture 92010)
2010: FDA approved the same drug under a different name (Xgeva) for a different use, as the first and only RANK Ligand inhibitor for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors (2010)
2011: Amgen, Watson Strike $400M Deal for Biosimilar Cancer Drugs (2011)
2013: Amgen Takes a Stab in China and Forms Pact With Zhejiang Beta Pharma Co. (2013)
2014: Amgen And Illumina Inc Enter Agreement To Develop
2014: Amgen drug lowers cholesterol up to 66 percent in pivotal studies
2014: Amgen's 2013 Revenues Increased 8 Percent To $18.7 Billion And Adjusted Earnings Per Share (EPS) Increased 17 Percent To $7.60
2014: Amgen's PCSK9 Scores Against Genetic High Cholesterol AMGN PFE REGN